Biotechnology company PepGen Inc. recently reaffirmed its clinical development timeline, clearly stating that it will release research data from the 5 mg/kg dose group in the Freedom-2 clinical trial in the first quarter of 2026.

The reiteration of this timeline provides clear expectations for investors focused on the treatment of neuromuscular diseases. In addition, for the higher-dose 10 mg/kg cohort, the company plans to announce relevant clinical results in the second half of 2026. The sequential disclosure of these two key data sets will gradually reveal the safety and efficacy of its candidate therapy in patients with Duchenne muscular dystrophy. The maintenance of this guidance reflects the company’s strict control over the clinical development process, and also provides an important time marker for the market to assess the value of PepGen Inc.’s technology platform and drug development potential.